The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
How AI and Data Are Shaping the Future of the Coast Guard
Deputy CIO Brian Campo says USCG is focusing its AI on efficiency, learning from peers and simplifying regulations for the maritime community.
17m watch -
NCI's Tech-Based Therapy Helps Patients Battle HPV-Linked Respiratory Disease
A new tech-based therapy is helping NCI treat patients who suffer from a respiratory illness associated with HPV.
23m listen -
CDC's Strategic Vision for Faster, Smarter Public Health Response
Dr. Jennifer Layden, a key architect of the CDC's Public Health Data Strategy, shares how modern technology is transforming disease detection and response.
9m listen -
Navy’s MOSA 1.0 Boosts Innovation, Interoperability
The Navy’s Modular Open Systems Architecture enables rapid prototyping, tech adoption and sharing of best practices across the Defense Department.
14m watch
